Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study
Phase 2
- Conditions
- Gram-Positive Bacterial Infections
- Registration Number
- NCT01212432
- Lead Sponsor
- University of Zurich
- Brief Summary
Daptomycin kinetics in CRRT
* Trial with medicinal product
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Pharmacokinetics 2011
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of daptomycin in treating Gram-Positive Bacterial Infections during continuous veno-venous hemodiafiltration?
How does daptomycin compare to standard-of-care antibiotics for Gram-Positive Bacterial Infections in critically ill patients undergoing CRRT?
Are there specific biomarkers that predict daptomycin efficacy in Gram-Positive Bacterial Infections during continuous renal replacement therapy?
What are the potential adverse events associated with daptomycin use in critically ill patients on continuous veno-venous hemodiafiltration?
What drug classes or combination therapies are being explored alongside daptomycin for Gram-Positive Bacterial Infections in patients with renal failure?